Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Escitalopram belongs to a group of antidepressants called selective serotonin reuptake inhibitors, or SSRIs. It works by increasing the amount of serotonin available in the brain. Serotonin is a chemical messenger that helps regulate mood, and increasing its availability can help reduce symptoms of depression and anxiety.
The medication is approved in Australia for treating major depression, generalised anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder. It stays in the body for around 30 hours after each dose, which means it takes a few days to build up to steady levels and a similar time to clear after stopping. The liver breaks it down through several enzyme pathways.
Common side effects that your family member might experience include nausea, diarrhoea, dry mouth, headache, and trouble sleeping. These often settle down after the first few weeks as the body adjusts to the medication.
More serious side effects are less common but need prompt medical attention. These include serotonin syndrome (symptoms like agitation, confusion, rapid heartbeat, high fever, or muscle stiffness), changes to heart rhythm, sudden eye pain or vision changes, and unusual bleeding or bruising (such as nosebleeds, bruising easily, or bleeding from the gums or stomach). There is also a documented risk of suicide attempt, particularly when starting or adjusting the dose.
Escitalopram cannot be used alongside certain other medications, including monoamine oxidase inhibitors (a type of older antidepressant) or pimozide (an antipsychotic). If your family member has ever had an allergic reaction to escitalopram or the related medication citalopram, they should not take it. The prescribing doctor will check for these interactions and any allergies before starting treatment.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationModerate to severe generalised anxiety disorder (GAD) Clinical criteria: The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria, AND Patient must not have responded to non-pharmacological therapy, AND Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared.
“Escitalopram is a highly selective Serotonin Reuptake Inhibitor (SSRI).”
“The elimination half-life (t ½ β ) after multiple dosing is about 30 hours and the oral plasma clearance (Cl oral ) is about 0.6 L/min.”
“Biotransformation of escitalopram to the demethylated metabolite is mediated by a combination of CYP2C19, CYP3A4 and CYP2D6.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Escitalopram is a highly selective serotonin reuptake inhibitor approved in Australia for the treatment of major depression, moderate to severe generalised anxiety disorder, moderate to severe social anxiety disorder, and obsessive-compulsive disorder. Biotransformation to the demethylated metabolite proceeds via CYP2C19, CYP3A4, and CYP2D6; the elimination half-life after multiple dosing is approximately 30 hours, with an oral plasma clearance of around 0.6 L/min. Concomitant use with monoamine oxidase inhibitors or the reversible MAOI moclobemide is contraindicated, as is co-administration with pimozide; at least 14 days must elapse after discontinuing escitalopram before starting an MAOI or RIMA, and 14 days after stopping an MAOI before commencing escitalopram.
Nausea, diarrhoea, dry mouth, headache, and insomnia are documented adverse effects. Serotonin syndrome, QT prolongation, angle-closure glaucoma, abnormal bleeding predominantly affecting skin and mucous membranes, and suicide attempt represent serious adverse effects that warrant clinical vigilance.
Working under the parallel aged-care framework? Aged-care equivalent →
Moderate to severe social anxiety disorder (social phobia, SAD) Clinical criteria: The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria, AND Patient must not have responded to non-pharmacological therapy, AND Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.